Scientists at the University of California, San Diego, have identified a new therapeutic target that could reduce heart and metabolic complications in patients with obstructive sleep apnea. This discovery hinges on the role of gut microbes in modifying bile acids, which play a crucial role in physiological disease pathways.
Sleep Apnea and Its Link to Bile Acids
Obstructive sleep apnea is a common disorder characterized by repeated breathing interruptions during sleep, leading to oxygen deprivation and increased carbon dioxide levels in the body. These conditions alter the composition of bile acids, transforming them into pathological chemical messengers that circulate in the bloodstream.
The Role of FXR Receptor in Arterial Plaque Accumulation
Researchers focused on a bile acid receptor known as the Farnesoid X Receptor (FXR). Experiments on genetically modified mice showed that removing this receptor significantly reduces the accumulation of fatty plaque in arteries, particularly in the aorta and aortic arch. This highlights the pivotal role of FXR in promoting fat accumulation in arteries under conditions resembling sleep apnea.
Mouse Experiments and Human Implications
The researchers compared two groups of mice: one predisposed to heart disease known as ApoE knock-outs, and another lacking the FXR receptor as well. When exposed to conditions mimicking sleep apnea, the results showed a significant reduction in arterial plaque accumulation in mice lacking FXR, along with stability in the gut microbiome.
Local Effects and Future Research
Despite the success in reducing plaque in major arteries, some accumulation still appeared in the pulmonary artery. This suggests that the impact of sleep apnea varies among blood vessels through different biological pathways. The team now aims to connect these findings with human clinical data and plans to conduct follow-up trials to test targeted bile acid or probiotic supplements for heart disease prevention.
Conclusion
This study suggests the potential use of microbe-mediated modified bile acids as a therapeutic approach for patients with obstructive sleep apnea. By targeting the FXR receptor, cardiac risks can be reduced and gut microbiome stability achieved. Further research is needed to understand the complex mechanisms and apply these findings to humans.